ABBV-RGX-314 is a new type of treatment called gene therapy for a condition called neovascular age-related macular degeneration (nAMD) or wet AMD. This eye problem causes vision loss because of leaky blood vessels in the retina, the part of the eye that helps you see. Current treatments require frequent eye injections, often every few weeks, which can be hard for patients to keep up with. This study is testing if ABBV-RGX-314 can be a one-time treatment instead of frequent injections. The study will look at how well it works and its safety. Up to 540 people will join the study, and they'll be divided into three groups. They want to see if ABBV-RGX-314 helps improve vision compared to another treatment, ranibizumab, over 54 weeks.

• Study length is about 54 weeks, with regular check-ups.
• Participants need to be between 50 and 89 years old.
• Must have been responsive to previous wet AMD treatments.